Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Glen Powell will host 'Saturday Night Live' with Olivia Dean as musical guest: What to know ahead of their debut - 2Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- 3Which Startup's Innovation Could Reform Medical care?
- 4Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- 5How to watch Dick Clark’s New Year’s Rockin’ Eve with Ryan Seacrest: Start time, TV channel, performers and more
- This Week In Space podcast: Episode 189 — Privatizing Orbit
- Figure out How to Establish a long term connection with Your Handshake
- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- These Cities Led Global Jet-Setting In 2025, According To New Data
- Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa
- Monetary Strengthening: Assuming Command over Your Cash
- Grasping the Elements of Medical caretaker Pay rates: Factors That Shape Your Pay
- Manual for Tracking down the Immaculate Magnificence of Focal Asia
